Welcome to our blog on precision oncology, "Cancer is Personal", a space dedicated to exploring how personalized, data-driven cancer treatments are transforming cancer care, improving outcomes, and minimizing side effects.

Search by Resource Topic:
Sort by Date Posted:
Search by Keywords:

Notable Early Successes in Precision Oncology: The Breakthroughs That Redefined Cancer Treatment

Introduction Precision oncology began gaining traction in the late 1990s and has since reshaped how we understand and treat cancer. Rather than classifying tumors solely by where they arise in the body, precision oncology asks a more fundamental question: What molecular alteration is driving this cancer? Our previous blog post: https://qualisuredx.com/precision-oncology-explained/ explored what precision oncology […]

Kira Grewal, MSc
March 3, 2026

5 min read

Prognostic Biomarkers for Papillary Thyroid Cancer: Reducing Overtreatment, Improving Clinical Efficiency, and Enhancing Patient Experience

Abstract Papillary thyroid cancer (PTC), the most prevalent form of thyroid malignancy, is generally indolent but poses a recurrence risk of 10%-15%, leading to a clinical paradox: the need to mitigate recurrence while avoiding overtreatment. Current prognostic frameworks, reliant on anatomical and histopathological factors, often result in inefficient treatment pathways, unnecessary surgical interventions, and increased […]

Qualisure Diagnostics Inc.
November 11, 2025

1 min read

Rethinking papillary thyroid cancer: Why “low risk” isn’t always low impact

This article discusses the limitations of current clinicopathologic approaches to risk stratification in papillary thyroid cancer and introduces Thyroid GuidePx® as a molecular diagnostic tool to better predict recurrence risk. It explains how traditional assessments based on imaging and histopathology can lead to both overtreatment and undertreatment, particularly because key prognostic information is often available […]

Qualisure Diagnostics Inc.
November 11, 2025

1 min read

Cancer care through molecular diagnostics: Addressing papillary thyroid cancer

Abstract Cancer care through molecular diagnostics: Addressing papillary thyroid cancer Oliver Bathe from the University of Calgary and Qualisure Diagnostics, walks us through addressing the surge in papillary thyroid cancer incidence by refining cancer care through molecular diagnostics. The incidence of papillary thyroid cancer (PTC) is rising by more than 6% in most developed countries, […]

Qualisure Diagnostics Inc.
November 11, 2025

1 min read

Thyroid GuidePx® is now cited in the 2025 ATA Guidelines.

Thyroid GuidePx® is now cited in the 2025 ATA Guidelines. This recognition highlights the growing role of molecular classifiers in papillary thyroid cancer — providing patient-specific recurrence risk to guide treatment decisions. It’s a proud milestone for Qualisure Diagnostics and for precision oncology. And it’s just the beginning. We remain committed to generating the evidence […]

Qualisure Diagnostics Inc.
November 6, 2025

1 min read

Prognostication With Thyroid GuidePX® in the Context of Tall Cell Variants

The tall cell variant of papillary thyroid cancer generally has a worse prognosis compared with the classical variant. Thyroid GuidePx is a genomic classifier capable of classifying papillary thyroid cancer into 3 molecular subtypes using fine-needle aspirate. Type 1 and 2 have low recurrence rates, particularly in early tumors (1–4 cm and N0). Type 3 is characterized by aggressive biology and high recurrence rates regardless of size and lymph node status.
Dr. Cynthia Stretch, CSO
October 28, 2024

2 min read
No more posts to show